Evaluation of in vitro chemosensitivity of vaccine-associated feline sarcoma cell lines to vincristine and paclitaxel

American Journal of Veterinary Research

Volumn 63, Issue 5, 2002, Pages 728-732

  Banerji, Nilanjana ^a   Li, Xia ^a   Klausner, Jeffrey S ^a   Kapur, Vivek ^a   Kanjilal, Sagarika ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; VINCRISTINE;

ANIMAL CELL; ARTICLE; CAT DISEASE; CELL COUNT; CELL CULTURE; CELL LINE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; SARCOMA CELL; TIME;

ANIMALIA; FELIDAE; FELIS CATUS;

EID: 0036246651     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.728     Document Type: Article

References (64)

1. Do injection site reactions induce fibrosarcomas in cats (lett)?
2. Postvaccinal sarcomas in the cat: Epidemiology and electron probe microanalytical identification of aluminum
3. Postvaccination sarcomas in cats
4. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats
5. Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992)
6. Feline fibrosarcomas at vaccination sites and non-vaccination sites
7. Vaccine site-associated sarcomas in cats: Clinical experience and a laboratory review (1982-1993)
8. Estimated prevalence of injection-site sarcomas in cats during 1992
9. Veterinary service market for companion animals, 1992. Part II: Veterinary service use and expenditures
10. Post-vaccinal sarcomas in the cat: Histology and immunohistochemistry
11. Feline vaccine-associated fibrosarcoma: An ultrastructural study of 20 tumors (1996-1999)
12. Genetically-engineered subunit vaccine against feline leukaemia virus: Protective immune response in cats
13. Current understanding of vaccination site-associated sarcomas in the cat
14. Aluminum hydroxide granulomas: Light and electron microscopic studies and X-ray microanalysis
15. Injection-site granuloma due to aluminum
16. Do postvaccinal sarcomas occur in Australian cats?
17. Fibrosarcoma at the site of a lufenuron injection in a cat
18. Use of immunohistochemistry and polymerase chain reaction for detection of oncornaviruses in formalin-fixed, paraffin-embedded fibrosarcomas from cats
19. Soft tissue sarcomas
20. Vaccine associated sarcomas in cats
21. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996)
22. Surgical excision of soft tissue fibrosarcomas in cats
23. Principles of treatment for soft tissue sarcoma
24. Radiation therapy and surgery for fibrosarcoma in 33 cats
25. Soft tissue sarcomas in the cat
26. Combined modality therapy in the treatment of solid tumors in cats
27. Osteosarcoma in cats: 22 cases (1974-1984)
28. Vincristine sulfate as single agent chemotherapy in a dog and a cat with malignant neoplasms
29. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors
30. Tumors of the skin and surrounding structures: Mesenchymal tumors
31. Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma
32. Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats with vaccine-associated sarcomas: 25 cases (1995-2000)
33. Review of treatment options for vaccine-associated feline sarcoma
34. Phase I evaluation of carboplatin in tumor bearing cats
35. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer
36. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer
37. Establishment of two vaccine-associated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone
38. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection
39. Comparative pharmacokinetics of antitumor Vinca alkaloids: Intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats
40. Phase I clinical and pharmacokinetic study of taxol
41. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
42. Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives
43. Taxanes: An overview of the pharmacokinetics and pharmacodynamics
44. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid
45. Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86
46. Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo
47. Treatment strategies for epidemic Kaposi's sarcoma
48. A phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma
49. Single-drug chemotherapy of canine transmissible venereal tumor with cyclophosphamide, methotrexate, or vincristine
50. Chemoimmunotherapy for canine lymphosarcoma
51. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma
52. Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases (1993-1997)
53. Chemotherapy: Properties, uses, and patient management
54. Uses of vincristine and vinblastine in dogs and cats
55. Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
56. Taxanes in the treatment of breast cancer: A prodigy comes of age
57. Role of taxanes in lung-cancer chemotherapy
58. A phase I study of ambulatory continuous infusion paclitaxel
59. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma
60. Phase II trial of paclitaxel in patients with soft-tissue sarcoma
61. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas
62. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: Proof of principle using dogs with spontaneously occurring tumors as a model
63. Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines
64. Overexpression of p21(wafl) decreases G2 M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein